<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To report the first case of pathologically confirmed <z:mp ids='MP_0001856'>myocarditis</z:mp> in a patient receiving treatment with lenalidomide for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>CASE SUMMARY: An 85-year-old woman with recurrent follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was treated with lenalidomide 10 mg daily and low-dose <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> 8 mg once weekly in a clinical trial </plain></SENT>
<SENT sid="2" pm="."><plain>She had a past medical history of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Within 17 days of starting lenalidomide and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>, she developed symptoms and signs of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Despite aggressive supportive care, she had progressive and refractory multiorgan failure and died </plain></SENT>
<SENT sid="5" pm="."><plain>Postmortem examination of the heart confirmed the absence of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, and histopathological examination of the myocardium revealed a diffuse lymphocytic/eosinophilic inflammatory infiltrate with associated <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myocardial injury affecting <z:hpo ids='HP_0000001'>all</z:hpo> 4 chambers of the heart, consistent with <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>DISCUSSION: Lenalidomide is an immunomodulatory agent derived from thalidomide and is approved for the treatment of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The efficacy of lenalidomide has been reported in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Common toxicities are <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:hpo ids='HP_0000988'>skin rash</z:hpo>, venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo>, and <z:e sem="disease" ids="C0853891" disease_type="Disease or Syndrome" abbrv="">tumor flare</z:e> reaction </plain></SENT>
<SENT sid="9" pm="."><plain>Cardiovascular toxicity has been limited to <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and an increased risk for venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0001890'>Autoimmune hemolytic anemia</z:hpo>, <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e>, and <z:hpo ids='HP_0000964'>dermatitis</z:hpo> have been described with lenalidomide </plain></SENT>
<SENT sid="11" pm="."><plain>We propose an immunological mechanism for <z:mp ids='MP_0001856'>myocarditis</z:mp> based on the predominantly T-cell infiltration of the myocardium </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Our findings suggest that lenalidomide may be a cause of drug-induced <z:mp ids='MP_0001856'>myocarditis</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>When patients treated with lenalidomide present with signs and symptoms of <z:hpo ids='HP_0001635'>heart failure</z:hpo> in the absence of other obvious causes, lenalidomide hypersensitivity should be considered in the differential diagnosis and a myocardial biopsy should be considered when other common causes of <z:hpo ids='HP_0001635'>heart failure</z:hpo> have been excluded </plain></SENT>
<SENT sid="14" pm="."><plain>A reasonable management approach is drug discontinuation and early institution of <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy </plain></SENT>
<SENT sid="15" pm="."><plain>An objective causality assessment, using the Naranjo probability scale, revealed that the adverse drug event was probable </plain></SENT>
</text></document>